How can we improve outcomes of chlamydia control programmes?  by Schachter, Julius & Chow, Joan M
Comment
www.thelancet.com/infection   Vol 16   September 2016 989
5 WHO. Interim guidance: clinical care for survivors of Ebola virus disease, 
11 April 2016. http://apps.who.int/iris/bitstream/10665/204235/1/WHO_
EVD_OHE_PED_16.1_eng.pdf (accessed April 29, 2016).
6 WHO. Emergency response to Ebola ﬂ are underway in Liberia. 
Case investigation widens to Guinea. 2016. http://who.int/csr/disease/
ebola/liberia-ﬂ areups-update/en/ (accessed 29 April 29, 2016).
7 Mattia JG, Vandy MJ, Chang, JC, et al. Early clinical sequelae of Ebola virus 
disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis 2016; 
16: 331–38.
8 WHO. Ebola virus disease: chronology of previous Ebola virus disease 
outbreaks. http://www.who.int/mediacentre/factsheets/fs103/en/ 
(accessed April 29, 2016).
How can we improve outcomes of chlamydia control 
programmes?
Chlamydia trachomatis, the most common sexually 
transmitted bacterial infection, can have important 
adverse con sequences for women’s reproductive 
health. Chlamydia can cause salpingitis, which can be 
either sympto matic (pelvic inﬂ ammatory disease) or 
asymptomatic, and its sequelae, ectopic pregnancy and 
tubal factor infertility.1 Given highly eﬀ ective therapy 
and excellent diagnostic tests, chlamydia control 
programmes to reduce and prevent adverse reproductive 
consequences have been initiated widely. In The Lancet 
Infectious Diseases, Bethan Davies and colleagues2 
present a careful evaluation and thoughtful discussion 
of the risks of reproductive complications in a nationally 
representative sample of Danish women after being 
tested (and presumably treated) for chlamydia infection. 
The study took advantage of Denmark’s com-
prehensive population register, which could be linked 
to hospital records for inpatient, outpatient, and 
emergency room visits and chlamydia test results. 
The investigators created a retrospective cohort of 
reproductive aged women (15–44 years old) who 
tested positive after Jan 1, 1995 (when chlamydia 
infection reporting was compulsory) and four matched 
controls who were not tested or had only negative 
chlamydia tests. This cohort (516 720 women: 
103 344 positive, 182 879 negative, and 230 497 never-
tested) is the largest group studied so far. Complications 
were captured until Oct 31, 2012, with mean follow-up 
of 8 years. 
As has been seen elsewhere, women with a positive 
chlamydia test were at a 30% or greater increased risk of 
pelvic inﬂ ammatory disease.3,4 There was also increased 
risk for ectopic pregnancy and tubal factor infertility as 
compared with women who were chlamydia-negative, 
but the impact on health was modest; the diﬀ erence 
in incidence of complications was small (pelvic 
in ﬂ ammatory disease 0·6%; ectopic pregnancy 0·2%; 
tubal factor infertility 0·1%). Repeat infections increased 
the risk of pelvic inﬂ ammatory disease by a further 
20%, again consistent with older studies.5 By contrast, 
complication risk was more than 60% lower in never-
tested women, suggesting criteria for testing eﬀ ectively 
identiﬁ ed those at risk. 
The obvious question is why is there excess risk for 
disease associated with chlamydia infection after 
diagnosis and treatment? With ectopic pregnancy 
and tubal factor infertility, the obvious answer is 
that these reﬂ ect previous Fallopian tube damage 
(scarring), which can occur with or without a previous 
symptomatic pelvic inﬂ ammatory disease episode. But 
why the excess risk of pelvic inﬂ ammatory disease? 
The intuitive answer is that chlamydia infection is a 
surrogate for other sexually transmitted infections 
that cause pelvic inﬂ ammatory disease. In Denmark, 
the incidence of gonorrhoea has been declining for 
years so gonococcal infection is not a likely candidate.6 
However, Mycoplasma genitalium or ascendance of 
bacteria associated with bacterial vaginosis could be 
other candidates.7 
But could the excess pelvic inﬂ ammatory disease 
risk associated with chlamydia infection still be due to 
chlamydia infection despite its having been diagnosed 
and treated? This is not a trivial question, and the 
answer could have important consequences for the 
design of comprehensive control programmes that 
go beyond screening. It is likely that answers to some 
questions are available from further examination 
of the dataset and were only partly addressed by 
adjustment for year of testing cohort. For example, 
what was the treatment rate for women diagnosed 
with chlamydia infections and for their partners? 
Were reinfections missed? Knowing the frequency 
of chlamydia testing for repeat screening of cases 
could help here. Although annual screening of 
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sexually active adolescent and young adult women 
is recommended, only in recent years has there been 
a major emphasis on repeat testing at 3 months 
after diagnosis to identify reinfection.8 Longer than 
recommended testing intervals could miss reinfections 
as these are likely to be of shorter duration than 
primary infections. What were the results of diagnostic 
tests done when pelvic inﬂ ammatory disease was 
diagnosed? Could secular changes in chlamydia test 
technologies or patient management have aﬀ ected 
the size of risk identiﬁ ed in this study? Antigen 
detection methods used during 1995–2000 could 
have missed 50% of infections detectable by second-
generation nucleic acid ampliﬁ cation tests available 
afterwards.9,10 Patients with pelvic inﬂ ammatory 
disease were once routinely admitted to hospital 
and diagnosis of ectopic pregnancy was determined 
surgically, but both transitioned predominantly to 
outpatient management.11 Because ascertainment of 
complications was based solely on hospital records, 
further work is needed to see if cohort members 
attended other primary care settings for milder 
presentations of complications. 
Answers to these questions could help deﬁ ne causes 
of excess risk of reproductive complications seen after 
a positive chlamydia test and inform more eﬀ ective 
interventions leading to improved outcomes. We look 
forward to further mining of this valuable dataset. 
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Equitable control of schistosomiasis and helminthiasis
Over the past decade, the continued high prevalence of 
some neglected tropical diseases (NTDs) has necessitated 
a revision of where and what kind of intensive control 
interventions are needed and what the associated 
targets are.1–4 Set within a global strategy  of preventive 
chemotherapy, as endorsed by WHO, the frontline public 
health method is routine co-administration by mass drug 
administration (MDA), of the anthelmintics praziquantel 
against schistosomiasis and albendazole against soil-
transmitted helminth iasis.5,6 In 2001, an ambitious target 
was set within resolution 54.19 of the World Health 
Assembly to attain regular treatment coverage of at 
least 75% in all school-age children at risk of morbidity. 
With noted progress falling short of this target by 
2010, in January, 2012, several substantial pledges and 
commitments were made at the London Declaration 
on NTDs with an additional World Health Assembly 
resolution 65.21, and both called for intensiﬁ cation of 
eﬀ orts to better rally resources and to ensure an adequate 
provision of medications. 
In The Lancet Infectious Diseases, Nathan Lo and 
colleagues7 show that striving towards 75% coverage 
should now be considered as the minimum standard 
of care in those communities targeted or deemed 
eligible for praziquantel and albendazole treatment. 
They describe novel cost-eﬀ ectiveness analyses of 
current MDA strategies, based on infection prevalence 
thresholds to explore putative outcomes of alternative 
prevalence thresholds as summed over a period of 
5 years, assuming 75% treatment coverage. Most 
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